GlassScriptPhysician profile
William David Sullivan
NPI 1659385276
$4,562.77
in general payments reported to CMS, 2019-2025
26 companies · $572 in 2025
The $572 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $633 · 2020: $299 · 2021: $723 · 2022: $687 · 2023: $817 · 2024: $832 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,220.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,116.70 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $619.09 | 2019-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $573.85 | 2022-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $506.50 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $413.59 | 2019-2024 | Xarelto |
| Amgen INC. | $258.39 | 2019-2024 | Repatha |
| Pfizer INC. | $246.23 | 2021-2025 | |
| Medtronic, INC. | $100.73 | 2021-2024 | Micra, Linq II |
| Medtronic Vascular, INC. | $81.84 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $73.20 | 2024 | Amvuttra |
| Inspire Medical Systems, INC. | $72.03 | 2024 | Inspire |
| Abbott Laboratories | $55.34 | 2020-2024 | Confirm Rx |
| Novo Nordisk INC | $54.35 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $52.17 | 2025 | |
| Glaxosmithkline, LLC. | $51.45 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $47.40 | 2023-2024 | Wainua, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $38.04 | 2024 | Cuvitru |
| Kiniksa Pharmaceuticals International, Plc | $35.25 | 2024 | Arcalyst |
| Baxter Healthcare | $32.50 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Heartflow, INC. | $30.02 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $24.35 | 2024 | |
| Sanofi-Aventis U.S. LLC | $21.89 | 2019 | |
| Ionis Pharmaceuticals, INC. | $17.75 | 2025 | Tryngolza |
| Hikma Pharmaceuticals USA | $14.57 | 2023 | Ryaltris |
| Leo Pharma INC. | $13.01 | 2023 | Adbry |
| Lilly USA, LLC | $12.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.